Presentation Highlights and Details – The abstracts are now available through the ISTH conference website

Sutacimig
Sutacimig showed sustained prophylaxis in GT (meaningful reduction in ATBR and high-intensity treatment events and use in surgical setting) in LTE portion of ongoing Phase 2 trial, with real-world and natural-history data underscoring the unmet need, and preclinical validation supporting expansion into FVIID with a Phase 2 proof-of-concept study underway; data expected late 2026 or early 2027.

Presentation Number: OC 57.3

Format: Oral

Title: Sutacimig Prophylaxis in Glanzmann Thrombasthenia: Results from a Phase 2 Long-Term Extension

Date and Time: July 14, 2026, 10:00 AM - 10:15 AM CEST

Presentation Number: OC 12.4

Format: Oral

Title: Elucidating Sutacimig’s Dual Mechanism in Factor VII Deficiency: TF-Pathway Enhancement via FVIIa Accumulation as the Significant Driver of Hemostatic Activity

Date and Time: July 12, 2026, 10:00 AM - 10:15 AM CEST

Presentation Number: PB3513

Format: Poster

Title: Persistent Weekly Bleeding Burden Across the Lifespan in Glanzmann Thrombasthenia: Analysis of the GT360 Patient Survey

Date and Time: July 14, 2026, 1:45 PM CEST

Presentation Number: PB3523

Format: Poster

Title: Elevated Depression Prevalence and Psychological Burden Associated with Bleeding Frequency in Glanzmann Thrombasthenia

Date and Time: July 14, 2026, 1:45 PM CEST

Presentation Number: PB3495

Format: Poster

Title: Substantial Bleeding Burden and Limited Prophylaxis Use in Glanzmann Thrombasthenia: Prospective Real-World Data from ATHN Transcends

Date and Time: July 14, 2026, 1:45 PM CEST

 

HMB-002
HMB-002’s first-in-human data from an ongoing Phase 1/2 clinical trial support a non-replacement subcutaneous approach that elevates endogenous VWF and FVIII, with sustained hemostatic elevations and no thromboembolic events observed; multiple dose assessment is currently underway to enable a potential new prophylaxis paradigm in VWD.

Presentation Number: OC 12.5

Format: Oral

Title: First-in-human investigation of HMB-002: a subcutaneous antibody for prophylactic management of Von Willebrand disease

Date and Time: July 12, 2026, 10:15 AM - 10:30 AM CEST

HMB-003

HMB-003 is a potent subcutaneous plasmin inhibitor with a durable half-life that blocks fibrinolysis independently of the plasminogen activation pathway (tPA or uPA). HMB-003 inhibited fibrinolysis with greater potency than tranexamic acid in a human whole-blood flow model and demonstrated long half-life in preclinical models, supporting infrequent dosing with potential across multiple high-unmet-need conditions; first-in-human studies are planned for the second half of 2026.

Presentation Number: OC 05.1

Format: Oral

Title: A long-acting peptide plasmin inhibitor with extended antifibrinolytic activity enabling once-per-cycle subcutaneous treatment for heavy menstrual bleeding: Preclinical development of HMB-003

Date and Time: July 11, 2026, 1:00 PM - 1:15 PM CEST

Presentation Number: OC 09.5

Format: Oral

Title: HMB-003, a long-acting peptide plasmin inhibitor, potently inhibits fibrinolysis and localizes with fibrin in a human whole blood microfluidic flow model

Date and Time: July 11, 2026, 2:00 PM - 2:15 PM CEST

Presentation Number: PB1414

Format: Poster

Title: Optimization of the Halo Fluorescence Fibrinolysis Assay: How Plasma Overlay and Timing Influence Antifibrinolytic Assessment

Date and Time: July 12, 2026, 1:45 PM CEST